



rhstruthers@gmail.com

519-374-9332

Monthly subscription US\$19.99

Know when to hold-em!
Know when to fold-em!
Know where to set stops!
Know when to run!
Never count your portfolio
Until the sells are done..

I am working on an article how the current mRNA technology in these shots is just like big scams in the past like BreX or Nortel. **Forget all the controversy about vaccines, simply look at mRNA as a new technology in an experimental phase. The technology is failing and the market is screaming this loud and clear.** I am quickly sending this shorter alert version today because both Moderna and BioNTech have **major, major break downs on their stock charts today.**

Today's mRNA scam is not just Canadian or US but world wide. The two top scam stocks to sell this go around are **Moderna (MRNA) and BioNTech (BNTX)**. **Pfizer (PFE)** is heavily involved but in a smart move they isolated themselves with a deal through BioNTech. Pfizer has numerous other drug products while Moderna just has the mRNA vaccine and is totally committed to this failing technology. BNTX has a handful of cancer treatments in trials but the stock has been totally driven by Covid-19, the mRNA, see charts next page. What is quite telling is the investment community might already be partly on to the scam as **MRNA and BNTX have fallen more than half from their peaks while Pfizer and another major drug company Merck have hardly dropped at all.**

All that said, I know it is controversial subject for many reasons, personal, family, professional. Your experience and mine could be completely different. Maybe you know many that got real sick or died from Covid and I know many that got real sick or died from the shots?

Forget all this controversy and look at these mRNA companies as investments. The market is speaking very loudly that something is wrong with this mRNA technology, look at the chart comparisons next page and today's action after that, with Put Option suggestions.

I believe today's sell off could be related to a new study out of Israel today.

The results are in for the Sheba Medical Center's landmark study of a fourth COVID-19 shot, which took place in Tel Aviv with the Pfizer-BioNTech ([PFE](#), [BNTX](#)) vaccine. While the trial was many times smaller than traditional studies (just 154 medical staff were given the extra booster in December), it is the only known study of the effects of a fourth dose. The findings are also preliminary and not yet published.

Quote: "The vaccine, which was very effective against the previous strains, is less effective against the Omicron strain," said Prof. Gili Regev-Yochay, a lead researcher in the experiment. "We see an increase in antibodies, higher than after the third dose. However, we see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections. The bottom line is that the vaccine is excellent against the Alpha and Delta [variants], for Omicron it's not good enough."

As a result, she is recommending a fourth shot be given to those at higher risk, but signaled that the current campaign, which offers the jab to anyone of 60, could be amended to only include even older groups.

Stocks totally reliant on mRNA vaccines – BNTX and MRNA

BioNTech



Moderna



Diversified big Pharma, PFE and MRK, both with Covid treatment pills



Pfizer



Merck

At one time I had both Pfizer and Merck in the Millennium index so I have followed these companies for many years. There is a huge difference on how investors view the top two companies to the bottom two. I believe investors are having some doubts about the future of the top two mRNA dependent companies. More and more data is coming out that these shots are not safe and effective. Investors are likely to do more due diligence than the public. [Moderna Insider sales raise huge concerns \(a year ago\)](#). They both peaked at the same time in early August and since then have lost over half their value. This was about the time much lower vaccine effective rates were being reported. **Get out of these mRNA drug companies, it is a badly failed technology and only a matter of time before the masses find out.** I will be watching for shorting opportunities with Put Options. I think that is today.

Moderna dropped below a strong support level of \$200 today, it is probably headed to \$150



Buy Moderna March 18, 2022, \$240 Puts around \$57.

BioNTech chart below



BioNTech also broke below strong support around \$200 today. It is probably headed to around \$125.

I would buy the March 18, 2022 \$200 Put for around \$38.

I would be looking to take profits in these in the next 3 to 4 weeks.

Copyright 2022, Struther's Resource Stock Report

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.